This project aims to organise the sampling of blood and tumor at key points of the standard of care of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC). This will allow to identify new potential predictive biomarkers of efficacy of immunotherapy and to investigate the evolution of the tumoral microenvironment after successive systemic treatments.
Patients with recurrent squamous-cell carcinoma of the head and neck not amenable to local therapy and/or with metastatic disease
Tumor directly accessible to clinical examination (tumor of oral cavity and of oropharynx) and/or cervical lymphadenopathy accessible to echography allowing to realise biopsy under local anesthesia
Indication to treatment by anti-PD1 immunotherapy according to French competent authority recommendations
Performance status 0, 1 or 2
Head and neck squamous cell carcinoma accessible to a local treatment
Cancer of nasopharynx, sinus or nasal cavity
Other histology than epidermoid
Patients with contraindication for anti-PD1 immunotherapy
Centre Paul Strauss
Lead sponsor
Centre National de la Recherche Scientifique, France
Collaborator
Institut National de la Santé Et de la Recherche Médicale, France
Collaborator